Harrow, Inc. Common Stock (HROW)

Price$33.19

Value ScoreD

Growth ScoreB

Momentum ScoreC

Favorite Metrics

Price vs S&P 500 (26W)-28.49%

Price vs S&P 500 (4W)-13.17%

VGM Score47.04

Market Capitalization$1.24B

All Metrics

P/CF (Annual)28.20x

Book Value / Share (Quarterly)$0.77

P/TBV (Annual)224.79x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)45.39%

Cash Flow / Share (Quarterly)$-0.11

Price vs S&P 500 (YTD)-40.42%

Gross Margin (TTM)74.11%

Net Profit Margin (TTM)-5.57%

EPS (TTM)$-0.41

10-Day Avg Trading Volume0.71M

EPS Excl Extra (TTM)$-0.41

Revenue Growth (5Y)40.99%

EPS (Annual)$-0.14

ROI (Annual)-1.74%

Gross Margin (Annual)75.05%

Net Profit Margin (5Y Avg)-14.03%

Cash / Share (Quarterly)$2.54

Revenue Growth QoQ (YoY)-7.59%

ROA (Last FY)-1.29%

Revenue Growth TTM (YoY)26.22%

EBITD / Share (TTM)$0.36

ROE (5Y Avg)-55.97%

Operating Margin (TTM)4.44%

Cash Flow / Share (Annual)$1.15

P/B Ratio43.10x

P/B Ratio (Quarterly)45.73x

Net Income / Employee (Annual)$-13,800

EV / Revenue (TTM)5.34x

Net Interest Coverage (TTM)0.94x

ROA (TTM)-3.92%

EPS Growth QoQ (YoY)-5.63%

EV / EBITDA (TTM)103.79x

EPS Incl Extra (Annual)$-0.14

Current Ratio (Annual)2.20x

Quick Ratio (Quarterly)2.16x

3-Month Avg Trading Volume0.78M

52-Week Price Return15.56%

EV / Free Cash Flow (Annual)33.55x

Revenue / Employee (TTM)$720,300

Tangible BV / Share (Quarterly)$0.06

P/S Ratio (Annual)4.54x

Asset Turnover (Annual)0.68x

52-Week High$54.85

Operating Margin (5Y Avg)3.04%

EPS Excl Extra (Annual)$-0.14

CapEx CAGR (5Y)5.08%

Tangible BV CAGR (5Y)-24.83%

26-Week Price Return-20.56%

Quick Ratio (Annual)1.93x

13-Week Price Return-8.24%

Total Debt / Equity (Annual)4.64x

Current Ratio (Quarterly)2.48x

Enterprise Value$1.43B

Revenue / Share Growth (5Y)31.46%

Asset Turnover (TTM)0.70x

Book Value / Share Growth (5Y)5.88%

Revenue / Employee (Annual)$730,000

Inventory Turnover (Annual)5.61x

Pretax Margin (Annual)-0.50%

Cash / Share (Annual)$1.96

3-Month Return Std Dev65.21%

Gross Margin (5Y Avg)73.23%

Net Income / Employee (TTM)$-40,100

EBITDA CAGR (5Y)62.32%

EBITDA Interim CAGR (5Y)39.57%

ROE (Last FY)-9.80%

Net Interest Coverage (Annual)0.52x

EPS Basic Excl Extra (Annual)$-0.14

P/FCF (TTM)28.29x

Receivables Turnover (TTM)3.01x

EV / Free Cash Flow (TTM)32.75x

Total Debt / Equity (Quarterly)10.18x

EPS Incl Extra (TTM)$-0.41

Receivables Turnover (Annual)2.40x

ROI (TTM)-5.08%

P/S Ratio (TTM)4.60x

Pretax Margin (5Y Avg)-13.57%

Revenue / Share (Annual)$7.41

Tangible BV / Share (Annual)$0.06

Forward P/E32.36x

Price vs S&P 500 (52W)-8.80%

Year-to-Date Return-32.27%

5-Day Price Return-2.70%

EPS Normalized (Annual)$-0.14

ROA (5Y Avg)-8.17%

Net Profit Margin (Annual)-1.89%

Month-to-Date Return-5.74%

Cash Flow / Share (TTM)$-0.15

EBITD / Share (Annual)$0.67

Operating Margin (Annual)8.36%

LT Debt / Equity (Annual)4.64x

P/CF (TTM)81.37x

ROI (5Y Avg)-9.96%

LT Debt / Equity (Quarterly)10.18x

EPS Basic Excl Extra (TTM)$-0.41

P/TBV (Quarterly)224.79x

P/B Ratio (Annual)34.60x

Inventory Turnover (TTM)5.11x

Pretax Margin (TTM)-4.16%

Book Value / Share (Annual)$1.41

Price vs S&P 500 (13W)-16.49%

Beta0.30x

P/FCF (Annual)28.93x

Revenue / Share (TTM)$7.22

ROE (TTM)-33.65%

52-Week Low$27.76

vGradeD

gGradeB

mGradeC

vgmGradeC

Show chart for

Earnings Surprise History

Q1 26-0.74est. -0.41

Analyst Recommendations

Feb 2026

Mar 2026

Apr 2026

May 2026

4.29

Industry Peers — Pharmaceuticals(550)

Symbol	Value Score	Growth Score	Momentum Score	Price
HROWHarrow, Inc. Common Stock	D	B	C	$33.19
LLYEli Lilly & Co.	D	B	B	$1131.42
JNJJohnson & Johnson	D	C	B	$232.77
ABBVABBVIE INC.	D	C	C	$227.23
MRKMerck & Co., Inc.	C	C	B	$120.79
NVSNovartis AG	C	C	C	$149.16
AZNAstraZeneca PLC	D	B	C	$185.95
NVONovo-Nordisk A/S	B	B	B	$42.96
ABTAbbott Laboratories	C	C	D	$91.07
PFEPfizer Inc.	B	C	C	$26.04
BMYBristol-Myers Squibb Co.	B	C	B	$57.27

About

Harrow Inc is a specialty pharmaceutical company that develops and commercializes ophthalmic medications for the U.S. market, including branded products like Iheezo, Vevye, and Maxitrol. The company generates revenue through its Branded segment and ImprimisRx platform, while advancing a clinical pipeline targeting conditions such as dry eye disease, glaucoma, and cataracts across both front and back-of-the-eye indications.